Semax
ACTH Analogue — Neuro-Enhancement and Neuroprotection
Semax is a heptapeptide analogue of ACTH(4-10) developed in Russia and used clinically there for stroke, cognitive impairment, and ADHD. As a nootropic, it is researched for its ab...
Formula
C37H51N9O10S
Molecular Weight
813.92 g/mol
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro
What is this compound?
Semax is a heptapeptide analogue of ACTH(4-10) developed in Russia and used clinically there for stroke, cognitive impairment, and ADHD. As a nootropic, it is researched for its ability to increase BDNF (Brain-Derived Neurotrophic Factor), enhance memory consolidation, and provide neuroprotective effects following ischemic events.
BDNF and NGF upregulation for neuroplasticity
Cognitive performance and memory enhancement
Attention, focus, and executive function support
Neuroprotection following ischemic or hypoxic events
Anxiolytic properties without sedation
Mood stabilization and depression research
How it works
Semax activates melanocortin receptors and significantly increases BDNF and NGF expression in the hippocampus and cerebral cortex. It modulates dopaminergic, serotonergic, and cholinergic neurotransmission. Its influence on HIF-1α may confer protective effects under hypoxic condi...
Research imagery
Areas of investigation
Discovery to present
1970s
Discovery
Semax was first identified and characterized in research contexts.
2000s
Research
Preclinical studies expanded across multiple tissue types and disease models.
2010s
Clinical Progress
Early-stage research progressed toward translational and clinical investigation.
2024+
Current Interest
Active research continues with growing scientific interest and expanding publication volume.
Knowledge connections
Explore how Semax connects to mechanisms, research goals, related compounds, and scientific references.
Research calculations
Plan research protocols with precise reconstitution, dosing, and unit conversion tools.
Reconstitution Calculator
Bacteriostatic water ratios
Dose Calculator
Precise microgram dosing
Unit Converter
Syringe unit conversions
Compare with similar compounds
Frequently researched together
These compounds are commonly studied alongside Semax for complementary mechanism effects.
Loading...
Loading...
Primary literature
Reference compilation in progress. See research highlights below.
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation
Studies show 3-4x increase in BDNF levels following administration
Studies show 3-4x increase in BDNF levels following administration
Attention and reaction-time improvements demonstrated in healthy subject research
Attention and reaction-time improvements demonstrated in healthy subject research
Semax — Frequently asked
Semax is a heptapeptide analogue of ACTH(4-10) developed in Russia and used clinically there for stroke, cognitive impairment, and ADHD. As a nootropic, it is researched for its ability to increase BD... Semax belongs to the Cognitive research category and is studied for its acth analogue — neuro-enhancement and neuroprotection.
Semax activates melanocortin receptors and significantly increases BDNF and NGF expression in the hippocampus and cerebral cortex. It modulates dopaminergic, serotonergic, and cholinergic neurotransmission. Its influence on HIF-1α may confer protective effects under hypoxic conditions.
BDNF and NGF upregulation for neuroplasticity. Cognitive performance and memory enhancement. Attention, focus, and executive function support. Neuroprotection following ischemic or hypoxic events. Anxiolytic properties without sedation. Mood stabilization and depression research.
Semax has the molecular formula C37H51N9O10S and a molecular weight of 813.92 g/mol. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro. This structural information is important for researchers studying receptor binding and pharmacokinetics.
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation Studies show 3-4x increase in BDNF levels following administration Attention and reaction-time improvements demonstrated in healthy subject research These findings are based on preclinical and clinical research. Semax is a research compound and these studies do not constitute medical advice.
No. Semax is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
Semax belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Add to your cart
Select a variant to add Semax to your cart for comparison, protocol planning, and AI-assisted analysis.
Available Variants
Research Disclaimer
Semax is a research compound. All information is for educational and research purposes only. Not intended for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.